Research analysts at BTIG Research started coverage on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $43.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 41.49% from the company’s current price.
Several other equities analysts have also recently weighed in on the company. BidaskClub cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. Goldman Sachs Group cut Crispr Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $78.00 to $40.00 in a report on Monday, January 28th. Citigroup cut Crispr Therapeutics from a “neutral” rating to a “sell” rating and cut their price target for the company from $28.00 to $21.00 in a report on Tuesday, January 22nd. Zacks Investment Research raised Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, January 3rd. Finally, SunTrust Banks reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Monday, December 31st. Three research analysts have rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Hold” and a consensus target price of $49.70.
NASDAQ CRSP opened at $30.39 on Thursday. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90. The stock has a market cap of $1.58 billion, a P/E ratio of -17.77 and a beta of 3.14.
In related news, President Rodger Novak sold 17,310 shares of the stock in a transaction that occurred on Tuesday, January 8th. The stock was sold at an average price of $35.09, for a total transaction of $607,407.90. Following the sale, the president now directly owns 1,130,697 shares in the company, valued at approximately $39,676,157.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Vertex Pharmaceuticals (Europe purchased 22,742 shares of the firm’s stock in a transaction that occurred on Friday, December 21st. The shares were acquired at an average price of $22.58 per share, for a total transaction of $513,514.36. The disclosure for this purchase can be found here. Over the last three months, insiders bought 153,682 shares of company stock valued at $3,700,718. 37.70% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. grew its position in Crispr Therapeutics by 96.7% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,627 shares of the company’s stock worth $46,000 after acquiring an additional 800 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Crispr Therapeutics by 79.4% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,987 shares of the company’s stock worth $112,000 after acquiring an additional 1,765 shares during the last quarter. LPL Financial LLC grew its position in Crispr Therapeutics by 24.4% during the 4th quarter. LPL Financial LLC now owns 9,809 shares of the company’s stock worth $280,000 after acquiring an additional 1,924 shares during the last quarter. Bank of America Corp DE grew its position in Crispr Therapeutics by 26.5% during the 2nd quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock worth $553,000 after acquiring an additional 1,972 shares during the last quarter. Finally, We Are One Seven LLC bought a new stake in Crispr Therapeutics during the 4th quarter worth approximately $57,000. Institutional investors and hedge funds own 43.71% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.